The company will pay USD 11.25 million each to the US federal government and the Texas state administration in 16 tranches spread over four years, besides paying USD 2.5 million as the cost of litigation.
Pharmaceutical major Glenmark on Wednesday said its US subsidiary will pay USD 25 million to the federal government there as well as to the Texas state administration to settle a pricing investigation.
The company will pay USD 11.25 million each to the US federal government and the Texas state administration in 16 tranches spread over four years, besides paying USD 2.5 million as the cost of litigation. "Our subsidiary Glenmark Generics Inc., USA has concluded the pricing investigation by the Texas Attorney General, USA.
Under the terms of the agreed settlement, there is no admission of liability. "Glenmark Generics will make a payment in 16 equal tranches of USD 1.56 million each quarter for next 16 quarters to the state of Texas," Glenmark said in a BSE filing.
Commenting on the settlement, Glenmark President, North America and Global API Business, Robert Matsuk said: "The settlement amount will not materially impact the organisation's cash-flow".
He further said: "We remain committed to continuing our mission of providing our customers with the finest generic pharmaceutical products in the US and complying with all applicable state and federal pricing requirements".
Elaborating on the settlement agreement, the company said: "Glenmark must pay the state of Texas a total of USD 11.25 million for the state's general revenue fund.
Because the Medicaid programme is jointly funded by the state and the US taxpayers, the federal government is entitled to a percentage of the settlement proceeds".
"The federal government's share is also USD 11.25 million. Additionally, the Texas Attorney General's Office will receive USD 2.5 million in attorneys' fees and costs," the company added.
Glenmark stock price
On April 08, 2015, Glenmark Pharma closed at Rs 884.00, up Rs 39.60, or 4.69 percent. The 52-week high of the share was Rs 901.20 and the 52-week low was Rs 546.60.
The company's trailing 12-month (TTM) EPS was at Rs 18.02 per share as per the quarter ended December 2014. The stock's price-to-earnings (P/E) ratio was 49.06. The latest book value of the company is Rs 107.12 per share. At current value, the price-to-book value of the company is 8.25.
Anda sedang membaca artikel tentang
Glenmark's subsidiary to pay $25mn to settle a pricing case
Dengan url
http://kebugaranhidup.blogspot.com/2015/04/glenmarks-subsidiary-to-pay-25mn-to.html
Anda boleh menyebar luaskannya atau mengcopy paste-nya
Glenmark's subsidiary to pay $25mn to settle a pricing case
namun jangan lupa untuk meletakkan link
Glenmark's subsidiary to pay $25mn to settle a pricing case
sebagai sumbernya
0 komentar:
Posting Komentar